BSH 2022 | Autologous transplantation in DLBCL and unmet needs
Keith Wilson, MBBS, FRCP, FRCPath, Cardiff University, Cardiff and Vale University Health Board, Cardiff, Wales, gives an overview of his presentation at BSH 2022, which focused on the role of autologous transplantation in the treatment of diffuse large B-cell lymphoma (DLBCL), as well as the unmet needs in this treatment approach. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Transcript (edited for clarity)
Today, we’re going to discuss the role of transplantation, particularly autologous transplantation, in treating diffuse large B cell lymphoma. The data for this goes back to 1995. And interestingly, over the 25 years since that first publication, there has not been any significant change. So today’s talk is, given that 25 years have elapsed, let’s look at transplantation a bit more closely and where the gaps still are in terms of unmet need, and do we have any contenders on the horizon to deal with that unmet need?
Today, we’re going to discuss the role of transplantation, particularly autologous transplantation, in treating diffuse large B cell lymphoma. The data for this goes back to 1995. And interestingly, over the 25 years since that first publication, there has not been any significant change. So today’s talk is, given that 25 years have elapsed, let’s look at transplantation a bit more closely and where the gaps still are in terms of unmet need, and do we have any contenders on the horizon to deal with that unmet need?
Read more...
